stockrowAffimed N.V.
AFMDQ Healthcare Biotechnology
Affimed N.V.’s revenue for fiscal 2023 (year ended December 2023) was $9.0 million, down 79.4% from fiscal 2022.
Follow AFMDQ
Alert me
Affimed N.V. (AFMDQ) EV/Sales
As of 6 November 2026, Affimed N.V. (AFMDQ) trades at a EV/Sales of −19.2×. Over the past ten years it has ranged from −19.2× (November 2026) to 155× (August 2018) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 3.1× | — |
| FY2022 | −0.2× | — |
| FY2022 | 9.7× | 3.48% |
| FY2021 | 9.4× | — |
| FY2021 | −3.6× | — |
| FY2020 | 9.8× | — |
| FY2020 | −4.0× | — |
| FY2019 | 2.6× | — |
| FY2019 | −3.7× | — |
| FY2018 | 2.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 36.7× | 96.09% |
| Jun 2024 | 18.7× | 47.92% |
| Mar 2024 | 12.7× | 310.12% |
| Dec 2023 | 3.1× | — |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AFMDQ Affimed N.V. | −19.2× |
| DCOY Decoy Therapeutics Inc compare | −3.5× |
| EOCN Eocene Ltd. compare | −3.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| BCAB BioAtla, Inc. compare | 0.7× |
| KALA KALA BIO, Inc. compare | 8.0× |
| ERNA Ernexa Therapeutics Inc. compare | 50.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)